Nutriband Partners with Brand Institute to Develop Global Brand Identity for AVERSA FENTANYL Abuse-Deterrent Patch

Nutriband Inc. (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, has announced a strategic partnership with Brand Institute, Inc. to develop the global commercial brand name and visual identity for AVERSA FENTANYL. This collaboration represents a significant step forward for what could become the world's first abuse-deterrent opioid patch, addressing critical public health concerns surrounding opioid medications.

The agreement was signed between Nutriband's subsidiary 4P Therapeutics and Brand Institute, a global leader in pharmaceutical brand name and identity development. AVERSA FENTANYL utilizes Nutriband's proprietary AVERSA(TM) abuse-deterrent transdermal technology, specifically engineered to deter misuse and reduce accidental opioid exposure. This technology represents a breakthrough in transdermal drug delivery systems, offering potential solutions to the ongoing opioid crisis affecting communities worldwide.

Brand Institute brings substantial expertise to this partnership, holding a remarkable 75% share of global drug name approvals and an impressive 87% of FDA-approved names in 2024. The initiative will be supported by Brand Institute's regulatory subsidiary, Drug Safety Institute, which employs former officials from major regulatory bodies including the FDA, EMA, Health Canada, USAN, and WHO. This regulatory experience is crucial for navigating the complex approval processes required for pharmaceutical products with abuse-deterrent properties.

The development of AVERSA FENTANYL addresses a critical gap in pain management therapeutics. Traditional fentanyl patches have been subject to misuse through various methods, including extraction of the active ingredient for unintended use. The AVERSA(TM) technology can be incorporated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. This innovation could significantly impact how potent opioids are prescribed and administered, potentially reducing the risk of addiction and overdose incidents.

For healthcare providers and patients, the introduction of an abuse-deterrent fentanyl patch could transform pain management protocols. Physicians may gain greater confidence in prescribing potent opioids for chronic pain conditions, knowing that additional safety measures are in place. Patients requiring strong pain relief could benefit from reduced risks of accidental exposure, particularly in households with children or individuals not prescribed the medication.

The partnership with Brand Institute ensures that the commercial launch of AVERSA FENTANYL will be supported by comprehensive brand development strategies. This includes creating a distinctive visual identity and brand name that communicates the product's safety features while maintaining regulatory compliance across global markets. The collaboration leverages Brand Institute's extensive experience in pharmaceutical branding, which can be explored further at https://ibn.fm/mB1fE.

As opioid abuse continues to be a significant public health concern, innovations like AVERSA FENTANYL represent important advancements in medication safety. The development of abuse-deterrent formulations aligns with regulatory priorities and public health initiatives aimed at reducing prescription drug misuse. Nutriband's technology platform offers potential applications beyond fentanyl, suggesting broader implications for the entire category of transdermal medications with abuse potential.

The successful development and commercialization of AVERSA FENTANYL could establish new standards for transdermal drug delivery systems, potentially influencing regulatory requirements and industry practices. As the partnership progresses, the pharmaceutical industry will be watching closely how this abuse-deterrent technology performs in clinical settings and how it might reshape approaches to pain management and drug safety worldwide.